Funding for this research was provided by:
Damon Runyon Cancer Research Foundation
Society for Immunotherapy of Cancer
American Society of Clinical Oncology
National Cancer Institute (U54 CA224086)
Text and Data Mining valid from 2018-09-26
First Online: 26 September 2018
Compliance with Ethical Standards
: The authors acknowledge support from the Damon Runyon Cancer Foundation Physician Scientist Training Grant (DL), ASCO Young Investigator Award (DL, RWJ), and Society for Immunotherapy of Cancer—Bristol-Meyers Squibb Postdoctoral Cancer Immunotherapy Translational Fellowship (DL), National Cancer Institute (Grant no. U54 CA224086) (RJS).
: David Liu declares he has no conflicts of interest that might be relevant to the content of this manuscript. Russell W. Jenkins has ownership interest in pending US Patent Application No. 15/540,346. Ryan J. Sullivan declares institutional funding from BMS, Merck, Novartis, Amgen, Immunocore, BiomedValley Discoveries, Lilly, Pfizer, Viralytics, Adaptimmune, Takeda, Tesaro, Genentech, Array Biopharma, Astex, Alglea, Asana, Sanofi, Infinity, Syndax, and Moderna; advisory board/consulting from Merck, Amgen, Array Biopharma, Syndax, Compugen, Genentech, and Novartis; and research funding from Amgen and Merck.